Skip to Content
Morningstar

SPDR® S&P Pharmaceuticals ETF XPH

Morningstar Medalist Rating
Medalist Rating as of | See State Street Investment Hub

Morningstar’s Analysis XPH

Will XPH outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

  • Process Pillar

    The Process Pillar is our assessment of how sensible, clearly defined, and repeatable XPH’s performance objective and investment process is for both security selection and portfolio construction.

  • People Pillar

    The People Pillar is our evaluation of the XPH management team’s experience and ability. We find that high-quality management teams deliver superior performance relative to their benchmarks and/or peers.

  • Parent Pillar

    The Parent Pillar is our rating of XPH’s parent organization’s priorities and whether they’re in line with investors’ interests.

SPDR ® S&P Pharmaceuticals ETF’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the lowest fee quintile among peers.

by Morningstar Manager Research
Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings XPH

More XPH Holdings
  • Current Portfolio Date
  • Equity Holdings —
  • Bond Holdings —
  • Other Holdings —
  • % Assets in Top 10 Holdings 48.5
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Intra-Cellular Therapies Inc

5.32 10.1 Mil
Healthcare

Merck & Co Inc

5.05 9.6 Mil
Healthcare

Catalent Inc

4.92 9.3 Mil
Healthcare

Eli Lilly and Co

4.88 9.3 Mil
Healthcare

Perrigo Co PLC

4.86 9.2 Mil
Healthcare

Organon & Co Ordinary Shares

4.83 9.2 Mil
Healthcare

Pfizer Inc

4.65 8.8 Mil
Healthcare

Jazz Pharmaceuticals PLC

4.63 8.8 Mil
Healthcare

Royalty Pharma PLC Class A

4.58 8.7 Mil
Healthcare

Johnson & Johnson

4.55 8.6 Mil
Healthcare